VBI Vaccines (VBIV) Earning Somewhat Favorable Press Coverage, Analysis Finds

News coverage about VBI Vaccines (NASDAQ:VBIV) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. VBI Vaccines earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.8465299072651 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Several equities analysts have issued reports on VBIV shares. Zacks Investment Research raised VBI Vaccines from a “sell” rating to a “hold” rating in a research note on Tuesday, September 19th. Canaccord Genuity started coverage on VBI Vaccines in a research note on Wednesday, November 1st. They issued a “buy” rating and a $10.00 price target on the stock. BMO Capital Markets started coverage on VBI Vaccines in a research note on Wednesday, November 15th. They issued an “outperform” rating and a $11.00 price target on the stock. Finally, BidaskClub lowered VBI Vaccines from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $8.75.

Shares of VBI Vaccines (NASDAQ VBIV) traded up $0.07 on Friday, reaching $4.46. The company’s stock had a trading volume of 127,911 shares, compared to its average volume of 191,804. VBI Vaccines has a 12-month low of $3.04 and a 12-month high of $6.60. The company has a current ratio of 1.03, a quick ratio of 0.97 and a debt-to-equity ratio of 0.19.

In other news, major shareholder Life Sciences Maste Perceptive bought 3,100,000 shares of the stock in a transaction dated Thursday, October 26th. The shares were bought at an average cost of $3.05 per share, with a total value of $9,455,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Opko Health, Inc. bought 655,738 shares of the stock in a transaction dated Monday, October 30th. The shares were purchased at an average cost of $3.05 per share, for a total transaction of $2,000,000.90. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 4,080,738 shares of company stock worth $12,480,151. Insiders own 54.50% of the company’s stock.

TRADEMARK VIOLATION WARNING: “VBI Vaccines (VBIV) Earning Somewhat Favorable Press Coverage, Analysis Finds” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/13/vbi-vaccines-vbiv-earning-somewhat-favorable-press-coverage-analysis-finds.html.

About VBI Vaccines

VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.

Insider Buying and Selling by Quarter for VBI Vaccines (NASDAQ:VBIV)

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply